Ann: MND Biomarkers and Pharmacodynamics Results, page-332

Im not disagreeing that loss of the cornerstone contract was a major blow. But, what led to this loss, what led to the inability to establish other significant contracts, why was there a lack of diverse value streams and also contracts.

All of those are management responsibilities. Not saying they are miracle workers, and it seems there was no saving epichem. But im not viewing epichem in isolation.

When viewed more broadly, it is just one more example of PAA failure. A pattern has formed. Yes individually they can all be "justified". At what point do you actually hold management to account and at least question them?